This study enrolled 536 patients who underwent successful coronary stenting with bare-metal stents and 6-month angiographic follow-up examinations between 1998 and 2000. Baseline characteristics and angiographic and procedural parameters for these patients were obtained. Primary endpoints were all-cause mortality and nonfatal myocardial infarction. Patients were assigned to instent restenosis or non-instent restenosis groups based on 6-month angiographic follow-up results. Restenosis inside a bare-metal stent was defined as more than 50% stenosis at the intervention site. In total, 178 (33.2%) patients had restenosis inside bare-metal stents, while 358 (66.8%) patients were without. At mean follow-up of 56.8 ± 20.3 months, 36 (6.7%) patients had a primary endpoint event while 500 (93.3%) patients had no primary endpoint event. Survival rates for patients free from primary endpoints in the instent restenosis and non-instent restenosis groups were 96.0 versus 99.4% at 1 year and 89.8% versus 94.8% at 5 years, respectively (P = 0.0033). Survival rates for patients free of all-cause mortality in the instent restenosis and non-instent restenosis groups were 96.0% versus 99.4% at 1 year and 91.6% versus 96.3% at 5 years, respectively (P = 0.0079). Multivariate Cox regression analysis showed that restenosis inside bare-metal stents was an independent predictor of primary endpoint events (odds ratio: 2.053; 95% CI: 1.048-4.022; P = 0.036) and was a predictor of total mortality with borderline significance (odds ratio: 2.036; 95% CI: 0.936-4.431; P = 0.073). In conclusion, in this study, restenosis inside bare-metal stents at 6-month angiographic follow-up was an independent predictor of long-term outcome-all-cause mortality and nonfatal myocardial infarction. Thus, this study provides clinical evidence that patients with restenosis inside bare-metal stents at 6-month angiographic follow-up likely warrant aggressive follow-up. (Int Heart J 2007; 48: 443-454) 
SINCE a stent was first introduced for managing acute vessel closure during balloon angioplasty in 1987, 1) coronary artery stenting has been shown to optimize the coronary lumen 2) and reduce procedural complications. 3, 4) Two large randomized trials demonstrated that intracoronary stenting with bare-metal stents substantially decrease the incidence of subsequent angiographic restenosis. 5, 6) Consequently, worldwide use of coronary stenting in place of balloon angioplasty increased. 7) Although coronary stenting with bare-metal stents avoids negative vascular remodeling and enhances overall vessel patency, restenosis develops in 10-60% of patients following successful coronary stenting and frequently requires subsequent revascularization. 5, 6, 8, 9) Drug-eluting stenting markedly reduced the incidence of restenosis. 10) However, drug-eluting stents are excessively costly for worldwide application and late stent-related thrombotic events are certainly cause for concern. 11, 12) Additionally, in several pooled analyses comparing sirolimus-eluting stents with bare-metal stents, no significant difference was found between the two treatments in rates of death, myocardial infarction, or stent thrombosis. 13, 14) Weintraub, et al 15) showed that restenosis that developed following successful balloon angioplasty has no adverse affect on long-term survival. However, clinical data regarding the impact of restenosis following successful coronary stenting with bare-metal stents on long-term clinical outcome is limited and inconclusive due to a lack of clinical data on noncardiac comorbidities such as diabetes mellitus and renal insufficiency and on medical therapy. 16) This study analyzed the impact of restenosis inside bare-metal stents on longterm clinical outcome, particularly patient survival, following successful coronary stenting in a large cohort.
METHODS
Patient population: Between 1998 and 2000, 536 consecutive patients who underwent percutaneous coronary stenting with bare-metal stents [acute coronary syndrome in 462 (86.2%) patients and angina pectoris in 74 patients (13.8%)] comprised the study population. A total of 605 coronary stents were implanted in the 536 patients. All patients underwent 6-month angiographic follow-up examinations. Procedural success was defined as successful stent implantation at the desired position with residual stenosis < 30% followed by Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow in the target vessel. 17) Patients with procedural complications, such as perforation, non-ST elevation myocardial infarction, acute stroke, no reflow phenomenon, ventricular tachyarrhythmia, or procedurerelated mortality were excluded. Procedure and protocol of coronary stent implantation : The study procedure and protocol have been described previously in detail. 18) All patients received 10000- 15000U of heparin intravenously prior to intervention. Most lesions were predilated with 1:1 ratio of balloons prior to bare-metal stent implantation. Most patients underwent poststenting dilatation with a high pressure balloon. Patients were treated with ticlopidine 250 mg twice daily or clopidogrel 75 mg daily for 4 weeks following stenting. Aspirin 100 mg PO once daily was prescribed indefinitely. Angiographic analysis and 6-month coronary angiography follow-up: Coronary angiographic morphology of target lesions was classified by at least the two best angiogram projections; Thrombolysis in Myocardial Infarction flow grade was assessed. Consensus was reached by two interventional cardiologists before and after stent implantation. Using a contrast-filled guiding catheter as the calibration standard, quantitative angiographic analysis of the percentage of minimal lumen diameter stenosis, reference lumen diameter, and lesion length were determined using a digital edge-detection algorithm and by selecting the end-diastolic frames demonstrating the stenosis in its most severe and non-foreshortened projection. 19) Quantitative angiographic analysis of the baseline and follow-up angiograms were performed using identical views and intracoronary injections of nitroglycerin 0.1-0.2 mg prior to contrast medium injection. Angiograms obtained at 4-9 months after stenting were included in the analysis of 6-month follow-up angiographic results. The need for subsequent angiography or angioplasty after 6-month angiographic follow-up was determined by the attending physician. All patients who received a second angioplasty during 6-month angiographic followup had a third angiographic follow-up. The start point of observation in patients who received a second angioplasty was put off until the third angiographic follow-up. Target lesion restenosis inside bare-metal stents was defined as > 50% diameter stenosis at the target lesion site on the follow-up angiogram. Data collection : The detailed baseline and follow-up data obtained included age, gender, coronary risk factors, angiographic morphologic features and results, number of diseased vessels, and clinical events such as revascularization of a target lesion or target vessel (angioplasty or bypass surgery), nonfatal myocardial infarction, and cardiac or noncardiac death.
The primary endpoints were all-cause mortality and nonfatal myocardial infarction. The secondary endpoint was all-cause mortality. Statistical analysis: Data are expressed as the mean ± SD. Continuous variables were compared using the unpaired t-test and categorical variables were compared using the chi-square test. Multivariate Cox regression analysis was used to determine the correlation between independent parameters and clinical events, including primary endpoints and all-cause mortality. Rates of event-free survival were calculated using the Kaplan-Meier method and compared using means of the log-rank test. Statistical analyses utilized SPSS for Windows version 10 (SPSS, Inc., IL, USA). Two-sided values of P < 0.05 were considered statistically significant.
RESULTS
Baseline characteristics of patients with and without restenosis inside bare-metal stents: Table I lists the baseline characteristics for patients in this study. There were 178 patients (33.2%) with restenosis inside bare-metal stents, including 28 patients (5.2%) with instent coronary occlusion, and 358 patients (66.8%) with no restenosis inside bare-metal stents on 6-month follow-up angiography. Most patients (72.5%) with restenosis inside bare-metal stents underwent a second angioplasty for restenotic lesions at the same time as follow-up angiography. Table II lists the baseline characteristics for patients with and without restenosis inside bare-metal stents. Both groups were matched for age and gender. Patients with restenosis inside bare-metal stents had a significantly higher prevalence of diabetes mellitus than patients without restenosis. Additionally, patients with restenosis inside bare-metal stents underwent coronary reintervention earlier than patients without restenosis inside bare-metal stents due to recurrent symptoms. Long-term clinical outcome of patients with and without restenosis inside baremetal stents: Clinical follow-up data were available for 480 of the 536 patients (89.6%). Fifty-six patients were lost during follow-up [19 patients (10.7%) in the instent restenosis group and 37 patients (10.3%) in the non-instent restenosis group (P = 0.904)]. As the start point of observation in patients who received a second angioplasty for instent restenosis was put off until the third angiographic follow-up, the mean follow-up duration was 48.3 ± 21.2 months in the instent restenosis group and 61.0 ± 18.4 months in the non-instent restenosis group (P < 0.001).
During the follow-up period, 14 patients (7.9%) died in the instent restenosis group and 13 patients (3.6%) died in the non-instent restenosis group (P = 0.035). Survival rates for free from all-cause mortality in the instent restenosis and non-instent restenosis groups were 96.0% versus 99.4% at 1 year and 91.6% versus 96.3% at 5 years, respectively (P = 0.0079) (Figure 1 ). Survival rates for free from all-cause mortality and nonfatal myocardial infarction in the instent restenosis and non-instent restenosis groups were 96.0 versus 99.4% at 1 year, and 89.8% versus 94.8% at 5 years (P = 0.0033) (Figure 2 ).
Long-term clinical outcome of patients with stable angina and patients with acute coronary syndrome: Patients with acute coronary syndrome are listed in Table II . There were 155 patients (87.1%) with acute coronary syndrome in the instent restenosis group and 307 patients (85.8%) with acute coronary syndrome in the non-instent restenosis group (P = 0.675). Only 74 patients (13.8%) were chronic stable angina patients. Twenty-three (31.1%) of the 74 stable angina patients had restenosis inside the bare-metal stents, and 155 (33.5%) of the 462 patients with acute coronary syndrome had restenosis inside the bare-metal stents (P = 0.675). The left ventricular ejection fractions of patients with chronic stable angina were higher than those of patients with acute coronary syndrome (66.4 ± 14.6% versus 58.5 ± 15.6%, P < 0.001). However, there was no significant difference in terms of freedom from primary endpoints between patients with chronic stable angina and patients with acute coronary syndrome. Survival rates for free from primary endpoints in the chronic stable angina and acute coronary syndrome groups were 96.9% versus 92.4% at 5 years, respectively (P = 0.1374). Survival rates for free Figure 1 . Kaplan-Meier estimates of the overall survival rates among patients with and patients without instent restenosis (ISR). Note that the overall survival rate at 5 years was significantly lower in the instent restenosis group than in the non-instent restenosis group (91.6% versus 96.3%, P = 0.0079).
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from all-cause mortality in the chronic stable angina and acute coronary syndrome groups were 96.9% versus 94.4% at 5 years, respectively (P = 0.3178). Predictors of primary endpoints and all-cause mortality: At mean follow-up of 56.8 ± 20.3 months, 36 patients (6.7%) met a primary endpoint and 500 patients (93.3%) had no primary endpoint events. Table III lists the baseline characteristics and angiographic findings for patients with and without primary endpoint events. Patients with primary endpoint events were significantly older than patients without primary endpoint events (P = 0.005). Moreover, patients with primary endpoint events had significantly higher prevalence of renal insufficiency than patients without primary endpoint events (P < 0.001). Patients with primary endpoint events also had a relatively higher prevalence of diabetes mellitus than patients without primary endpoint events, although the difference did not reach statistical significance (P = 0.079). Univariate analysis determined that the incidence of restenosis inside bare-metal stents was significantly higher in patients with primary endpoint events than in patients without primary endpoint events (P = 0.027) (Table III) . Multivariate Cox regression analysis demonstrated Figure 2 . Kaplan-Meier estimates of the mean rates of freedom from primary endpoints among patients with instent restenosis (ISR) and patients without instent restenosis. Note that the survival rate of freedom of primary endpoints at 5 years was significantly lower in the instent restenosis group than in the non-instent restenosis group (89.8% versus 94.8%, P = 0.0033).
that restenosis inside bare-metal stents was an independent predictor of primary endpoint events (Table IV) . In addition, two other variables were independently related with primary endpoint events: renal insufficiency and age (Table IV) . Furthermore, multivariate Cox regression analysis indicated that restenosis inside bare-metal stents was a predictor of all-cause mortality with borderline significance (P = 0.073) ( Table V) . Three variables were independently correlated with all-cause mortality: renal insufficiency, age, and diabetes mellitus (Table V) . 
DISCUSSION
This study examined the impact of restenosis inside bare-metal stents on long-term clinical outcome, particularly survival, following successful coronary stenting. An important finding was that 6-month restenosis inside bare-metal stents is an independent predictor of long-term outcome -all-cause mortality and nonfatal myocardial infarction.
Six-month angiographic restenosis inside bare-metal stents as a primary determinant of long-term clinical outcome after coronary stenting: Weintraub, et al 15) showed that restenosis following successful balloon angioplasty is a determinant of a high rate of myocardial infarction and not survival. However, only 11.7% of the patients in their study had diabetes and patients with acute coronary syndromes were excluded. The mortality rate in their relatively low risk study population was very low, with a 6-year survival of 95% for patients without restenosis and 93% for patients with restenosis. Conversely, Van Belle, et al 20) showed that patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up is a primary determinant of survival following coronary balloon angioplasty in diabetics.
Schuhlen, et al 16) showed that angiographic restenosis detected by routine follow-up angiography is an independent predictor of a high 4-year mortality rate in patients with coronary stent placement, as was advanced age. However, in that study, data for noncardiac comorbidity were limited, and comprehensive data for symptoms of patients undergoing follow-up angiography and that for medical therapy during the follow-up period were unavailable. Notably, 31.3% of patients in our study had diabetes. The higher prevalence of diabetics in the instent restenosis group may account for the higher long-term all-cause mortality rate compared to that in the non-instent restenosis group (Table II) .
In this study, 6-month angiographic restenosis inside a bare-metal stent is a significant predictor of long-term clinical outcome -all-cause mortality and nonfatal myocardial infarction. However, restenosis inside bare-metal stents was only a predictor of all-cause mortality with borderline significance (P = 0.073). Most patients in the instent restenosis group received a second angioplasty procedure, and all these patients had the third angiographic follow-up. However, some patients who died without receiving the third angiography were excluded in order to adjust the status of coronary revascularization during follow-up, and this might cause underestimation of all-cause mortality in the instent restenosis group.
Renal insufficiency, diabetes mellitus, and advanced age as independent predictors of all-cause mortality: Rubenstein, et al 21) showed that patients with renal failure (creatinine > 1.5 mg/dL) had a lower survival rate and greater major adverse cardiac events rate at long-term follow-up than patients with normal renal function following balloon coronary angioplasty. In this study, renal insufficiency (creatinine ≥ 1.5 mg/dL) was strongly and independently correlated with long-term allcause mortality following coronary stenting. Lemos, et al 22) also showed that patients with renal impairment had a high mortality rate at 1 year and no differences in mortality between patients who received bare stents and those who received sirolimus-eluting stents; furthermore, restenosis was not a likely contributing factor increasing the mortality rate for patients with impaired renal function. In this study, 12 patients (19.0%) with renal insufficiency died in the longterm follow-up, while only 15 patients (3.2%) without renal insufficiency died in the same observation period (P < 0.001). Multivariate Cox regression analysis demonstrated that renal insufficiency was the most important predictor of longterm all-cause mortality (P < 0.001) ( Table V) .
In this study, diabetes mellitus was an independent predictor of all-cause mortality. Several coronary interventional studies showed that diabetes is associated with a poor long-term outcome after percutaneous coronary intervention, reflecting increased cardiovascular comorbidity and a high restenosis rate as a result of accelerated atherosclerosis and worsening renal function in diabetics. 20) Coronary interventional studies showed that age is an independent predictor of in-hospital and late mortality following percutaneous coronary intervention. 23, 24) In this study, advanced age was associated with an increase in the odds ratio for all-cause mortality of 1.062 per year, likely reflecting a comorbid condition. Clinical implications: Routine angiographic follow-up is difficult in daily clinical practice. However, a coronary balloon angioplasty study showed that clinical symptoms at follow-up were not correlated with survival. 20) This study showed that restenosis inside bare-metal stents at 6-month angiographic follow-up was independently correlated with long-term clinical outcome, including total mortality and nonfatal myocardial infarction, even after repeated angioplasty. Compared to bare-metal stents, drug-eluting stents have lower incidences of instent restenosis. However, that advantage is mitigated by the increased long-term unto-Vol 48 No 4 ward events of late stent thrombosis in drug-eluting stents.
12 ) The impact of angiographic restenosis inside drug-eluting stents on long-term clinical outcome remains unknown. As also suggested by other studies, 16, 25) instent restenosis is not a benign process, and our study provides clinical evidence that patients with restenosis inside bare-metal stents at 6-month angiographic follow-up likely warrant aggressive follow-up. Thus, our study raises the clinical issue that the impact of restenosis inside drug-eluting stents on long-term clinical outcome should be investigated by large scale studies in the future. Study limitations: This study has several limitations. First, this is a retrospective analysis of data in an interventional database for a consecutive series of patients. Second, patients with restenosis inside bare-metal stents at 6-month angiographic follow-up were not randomized to target lesion revascularization versus no target lesion revascularization. However, most patients (72.5%) with restenosis inside bare-metal stents at 6-month angiographic follow-up underwent a second angioplasty procedure for restenotic lesions and all these patients had a third angiographic follow-up. Moreover, patients who did not undergo the third angiography after the second angioplasty procedure were excluded in order to adjust the status of coronary revascularization during follow-up. Conclusions: In this study, restenosis inside bare-metal stents at 6-month angiographic follow-up was an independent predictor of long-term outcome defined by all-cause mortality and nonfatal myocardial infarction.
